The Food and Drug Administration has approved PARP inhibitors to treat metastatic prostate cancer patients with DNA repair deficiencies due to pathogenic variants in genes involved in homologous recombination repair (HRR), including BARD1. This evidence concerns the gene BARD1 and prostate cancer.